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Abstract In bone status assessment, proper quality
assurance/quality control is crucial since changes due to
disease or therapeutic treatment are very small, in the
order of 2–5%. Unlike for dual X-ray absorptiometry,
quality control procedures have not been extensively
developed and validated for quantitative ultrasound
technology, limiting its use in longitudinal monitoring.
While the challenge of developing an ideal anthropo-
metric phantom is still open, some manufacturers use
the concept of the internal digital phantom mimicking
human characteristics to check the stability of their de-
vice. The objective of the study was to develop a sensi-
tive model of quality control suitable for the correction
of QUS patient data. In order to achieve this goal, we
simulated a longitudinal device lifetime with both cor-
rect and malfunctioning behaviors. Then, we veriﬁed the
eﬃciency of digital phantoms in detecting those changes
and subsequently established the in vitro/in vivo rela-
tionship. This is the ﬁrst time that an attempt to validate
an internal digital phantom has made, and that this type
of validation approach is used. The digital phantom
(DP) was designed to mimic normal bone (BUAP2) and
osteoporotic bone (BUAP1) properties. The DP was
studied using the UBIS 5000 ultrasound device (DMS,
France). Diverse malfunctions of the UBIS-5000 were
simulated. Several series of measurements were per-
formed on both BUAP1 and 2 and on 12 volunteers at
each grade of malfunction. The eﬀect of each simulated
malfunction on in vivo and in vitro results was presented
graphically by plotting the average BUA values against
the percentage change from baseline. The change from
baseline in BUA was modeled using linear regression,
and the in vivo/in vitro ratio was obtained from the
model. All experimentations inﬂuenced the measure of
BUAP1 and 2 as well as the measure of our 12 volun-
teers. However, the degree of signiﬁcance varied as a
function of the severity of the malfunction, and the
results also diﬀered substantially in magnitude between
in vivo and in vitro. Indeed, the DP was about 10 times
more sensitive to variations of the transfer function than
was the in vivo measurement, which is very reassuring.
The sensitivity of the digital phantoms was reliable in the
determination of simulated malfunctions of the UBIS-
5000. The digital phantoms provided an accurate eval-
uation of the acoustic performance of the scanner,
including the ﬁdelity of transducers. In light of these
results, the QC approach of the UBIS-5000 will be
extremely simple to implement compared with other
devices. Indeed, since the digital phantom was auto-
matically measured during every patient measurement,
the QC approach could be built on an individual level
basis rather than on an average basis.
Keywords Internal digital phantoms Æ Monitoring Æ
Quantitative ultrasound device Æ UBIS 5000
Introduction
Quality assurance (QA) in bone status assessment in-
volves performance evaluation of the equipment and the
operator in order to improve the reliability of the results.
Quality control (QC), on the other hand, is an composite
of sampling and statistical testing procedures designed
to ensure adequate quality of the ﬁnished product. In
bone status assessment, proper QA is crucial, since
changes due to disease or therapeutic treatment are very
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small, of the order of 2–5%. Sources of error include
both measurement errors and equipment malfunction
[1,2,3]. Van Daele et al. reported an upward trend over 3
years for SOS and a downward trend for BUA of an
Achilles device, explained by a slight narrowing of the
distance between the transducers over time [4]. Similarly,
Krieg et al. mentioned in the Semof multicentre study
that both the Achilles and the Sahara ultrasound devices
shown signiﬁcant ﬂuctuations over time which probably
aﬀect the in vivo results. He reported that over a 2-year
period, 21 interventions were performed on the ten
Sahara devices (seven calibrations and 14 pads replace-
ments), while on the ten Achilles devices there was still a
signiﬁcant trend of changes over time (adjusted for
temperature) ranging from )0.8 to +0.6 dB/MHz per
year for BUA, and from+2.1 to +5.1 m/s year for SOS
[5]. Hans et al., in the Epidos multicentre study, showed
signiﬁcant diﬀerences between QUS devices of the same
brand for the SOS up to 6 m/s in vitro and 8 m/s in vivo,
but not for BUA, explained by the narrow dynamic
range and the temperature dependence of the SOS [6].
Similar diﬀerence (up to 11 m/s for the SOS) has been
also reported by Krieg et al. [5]. These magnitudes of
diﬀerence correspond for some studies at the average
diﬀerence between osteoporotic patients and age mat-
ched controls [7].
Equipment stability or malfunction can be monitored
using a bone-equivalent phantom. Phantoms are impor-
tant components of a QA program. In order to emulate
the in vivo measurement as closely as possible in terms of
geometric and acoustic properties, the phantom should
ideally be anthropomorphic [2,8]. It is hoped that changes
in the scanner which aﬀect the in vivo measurements will
also aﬀect the phantommeasurements in the samemanner
and thus be detected by the QC program, and that the
variations of the in vivo results may be predicted from the
phantom-based device calibration. As a result, one can
correct patient measurements for the eﬀect of an unstable
device based on the drift or shift of the phantom mea-
surements by applying a correction factor to the patient
data. This procedure would guarantee that the patient
data reﬂect the ‘‘biological or therapeutic’’ reality and are
not aﬀected by device malfunctions.
Appropriate QA and QC procedures have been well
developed and validated for dual X-ray absorptiometry
(DXA). These are now widely applied to multicenter
clinical trials in order to monitor DXA devices used to
assess treatment eﬀects on bone mineral density [9,10].
However, this is not the case for quantitative ultrasound
technology, for which almost no QC approach has been
tested in clinical trials [11].
Anthropomorphic phantoms used for DXA are rel-
atively simple in construction and the interaction
between X-rays and bone-equivalent phantoms is well
known. This is again not the case for quantitative
ultrasound, for which the theory of propagation through
cancellous bone is quite complex and not well under-
stood. As a result, the manufacturing of an anthropo-
morphic phantom speciﬁc for ultrasound is very diﬃcult
and expensive. Presently, there are no universally
accepted phantoms, but only ‘‘manufacturer speciﬁc’’
phantoms that are not anthropomorphic and whose
daily changes may not reﬂect what occurs in vivo. In
general, these phantoms consist of a piece of geometri-
cally shaped, homogenous material designed to simulate
the typical values of frequency-dependent attenuation
and speed of sound encountered in vivo in cancellous
bone, regardless of the actual geometry and spatial non-
homogeneity of the skeletal tissue. These materials are
well suited to help monitoring equipment drift or to
detect electro-acoustic or electronic malfunctions (i.e. to
detect any variations over time of the measuring device
transfer function), although the reliability of these
phantoms may be aﬀected by external factors such as
storage, aging and temperature [2,8]. The positioning of
the phantom during the scan acquisition could also lead
to monitoring errors due to possible non-homogeneity in
the composition of the phantom material. Several non-
ultrasound device manufacturers have also developed
such external ‘‘ultrasound speciﬁc’’ phantoms which are
still under evaluation for quantitative ultrasound (QUS)
assessment, such as the Leeds QUS phantom and the
Vancouver phantom [2,8,12]. The Leeds phantoms come
in three varieties that have diﬀerent QUS values in the
clinical range. Although potentially interesting, these
phantoms are very much temperature and positioning
dependent. The Vancouver phantom, on the other hand,
consists of a reticulated vitreous carbon form ﬁlled with
heavy grade USP oil. Similar to the Leeds phantom, the
Vancouver phantom comes in several varieties that have
diﬀerent properties. This phantom set has BUA in the
clinically relevant range (24–70 dB/MHz), but velocity
(1650 m/s) does not change with porosity as is seen in
vivo. Positioning is less of an issue, but temperature
adjustment is also needed.
To overcome the diﬃculties encountered in using
external phantoms (instability, aging, poor spatial
homogeneity), Langton has suggested using an internal
electronic phantom consisting of an electronic ﬁlter at-
tached to the receiving probe, and speciﬁcally designed
to reproduce the frequency ﬁltering eﬀect of the can-
cellous bone on the received ultrasonic signal [13]. The
concept of an internal phantom has been extended by
Laugier, who proposed the use of internal digital
phantoms [14]. Designed to test scanner performance for
broadband ultrasound attenuation (BUA) measure-
ment, Laugier’s approach does not require any addi-
tional hardware, but simply uses the signal transmitted
through a temperature-controlled water bath and com-
bines several device responses obtained at various input
voltages. According to Laugier, such phantoms are very
stable as they do not require any manipulation during
the measurement and are not inﬂuenced by external
factors such as aging or temperature. The digital BUA
phantom concept has already been implemented into
one QUS device (UBIS 5000; DMS, Montpellier,
France). However, the use of digital BUA phantoms to
simulate both normal and osteoporotic bone properties
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raises a series of questions: (1) are digital phantoms
eﬃcient in detecting any drift or shift in the machine?
Consequently, could they be used to monitor the sta-
bility of QUS devices? (2) Since an internal digital
phantom does not require a physical object between the
transducers and by nature is not an anthropomorphic
phantom, is the in vivo situation well simulated? (3) Is
the hypothesis ‘‘the ratio variation in vivo/in vitro equals
one’’ valid? (4) Could digital phantoms be used for
longitudinal QC in clinical settings?
In order to validate a new phantom, one should
ideally follow a QUS device over a long period of time
with daily phantom and patient measurements, hoping
that several malfunctions would occur. However, the
feasibility of such a study is almost impossible since the
patient’s values change biologically over time and
the well-characterized malfunctions are not very likely to
occur frequently enough.
The objective of the study was to develop a sensitive
model of quality control suitable for the correction of
QUS patient data. In order to achieve this goal, we
simulated a longitudinal device lifetime with both cor-
rect and malfunctioning behaviors. We then veriﬁed the
eﬃciency of digital phantoms in detecting those changes
and subsequently established the in vitro/in vivo rela-
tionship. This is the ﬁrst time that an attempt to validate
an internal digital phantom is made and that this type of
validation approach is used.
Material and methods
We evaluated the behavior of digital phantoms in several
situations by simulating diﬀerent malfunctions of the
UBIS-5000 ultrasound device.
UBIS 5000 description
The UBIS-5000 device is a water-based QUS system. It
generates ultrasound images of the calcaneous using a
pair of broadband-focused transducers (center fre-
quency 0.5 MHz, diameter 29 mm, focus 50 mm) sub-
merged in a water bath [14,15,16]. The device is
equipped with a thermostat that maintains the water
temperature at 30±2C. The measured parameter is the
BUA. The ultrasonic attenuation in bone varies quasi-
linearly with frequency in the commonly used frequency
bandwidth (200–800 kHz). The BUA represents the
slope of a linear regression ﬁt to the measured fre-
quency-dependent attenuation. The frequency-depen-
dent attenuation is obtained from the ratio of the
Fourier spectrum between a pulse transmitted through
the bone and the Fourier spectrum of a reference pulse
transmitted through water.
Digital phantom description
The digital phantom was designed to mimic normal
bone (BUAP2) and osteoporotic bone (BUAP1) prop-
erties. The BUA values are registered for both digital
phantoms during each in vivo or in vitro examination.
The results are then displayed in the QC section of the
UBIS software for each examination.
By applying diﬀerent voltages (i.e. 200 V, 63 V, 20 V
and 2 V) to the transmitting probe to measure the ref-
erence pulse through water, diﬀerent attenuations can be
simulated. Using 200 V as a reference, these voltages
correspond to attenuations of 0, 10, 20 and 40 dB,
respectively. As shown in Fig. 1, the Fourier spectra of
signals transmitted through water without any external
phantoms and using the voltages mentioned above have
similar shapes but diﬀerent amplitudes. As a conse-
quence, the spectral diﬀerences obtained using the 200 V
spectrum as a reference result in attenuation curves
which are frequency-independent, as shown in Fig. 2.
The amplitude spectrum of the diﬀerent reference signals
may be combined in order to simulate the attenuation
eﬀect as a function of frequency. For example, by
combining the value of the attenuation obtained at
250 kHz with the voltage at 63 V and the attenuation at
Fig. 1 Ampliﬁcation curves:
three attenuations can be
calculated by using the voltages
63 V, 20 V and 2 V and
considering the value of 200 V
as a reference
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500 kHz with the 20 V voltage, and by calculating the
slope of attenuation between those two frequencies, a
slope of (20 dB)10 dB)/250 kHz=40 dB/MHz is ob-
tained. Figure 3 illustrates an example of this type of
combination. The slope of the dotted curve is 40 dB/
MHz. This value corresponds to the BUA of an osteo-
porotic woman. Similarly, combining the value of the
attenuation obtained at 250 kHz with the voltage at
20 V and the attenuation at 500 kHz with the 2 V will
result in a slope of 80 dB/MHz, which is representative
of the average BUA for a young non-osteoporotic sub-
ject. As demonstrated, two diﬀerent values of BUA were
obtained from reference measurements in water with
diﬀerent input voltages. These two values are believed to
represent normal and osteoporotic digital phantoms.
Studied population
Eight women and four men, aged from 28 to 72 years
(mean age 41±14.3 years), recruited within the
employees or their relatives of the Nuclear Medicine
Division of the Geneva University Hospital, were mea-
sured (two measurements for each time point) on the
UBIS-5000 device in normal conditions and during the
simulated malfunctions described hereafter. The inclu-
sion of both sexes in our study ensured that the mea-
sured values covered a large range of BUA. None of the
subjects had ankle edema or conditions or treatment
known to aﬀect bone metabolism. The characteristics of
the population are presented in Table 1. Baseline mea-
surements were taken between each set of malfunctions.
Simulated malfunctions
The malfunction program was established in collabora-
tion with the maintenance department of the DMS
company in order to mimic the most frequent break-
downs of the ultrasonic probes or acquisition electron-
ics. The following situations were investigated: variation
of the transfer function at reception and emission,
modiﬁcation of footbath temperature and malfunction-
ing transducers. The impact of simulated malfunctions
was assessed in all subjects.
Variation of the transfer function at reception
The malfunction most frequently observed on the UBIS-
5000 device was a deterioration of the ultrasound signal
(e.g. caused by a broken probe). We therefore simulated
a variation of transfer function at the reception stage.
Figure 4 represents the system before modiﬁcation, i.e.
the standard commercial version. The reception stage is
composed of two ampliﬁers, A1 and A2. The ﬁrst
ampliﬁer A1 has a ﬁxed gain of 6 dB. The second
ampliﬁer A2 has a variable gain between 0 and 60 dB.
The high frequencies are then eliminated using a low-
pass ﬁlter with a cutoﬀ frequency of 4 MHz. The signal
is then converted by an analog-to-digital converter
(ADC), and transmitted to a PC-based computer for
Fig. 2 Attenuation curves via
the signal of 200 V
Fig. 3 Function of simulated attenuation: to obtain the BUA of
80 dB/MHz, corresponding to the average BUA value for a young
non-osteoporotic population, the combination of 20 dB and 40 dB
signals should be used
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digital signal processing. The computer then adjusts the
gain of A2 in real time, so that the received signal
amplitude always ﬁts the dynamics of the ADC.
Changing the gain of A1 (6 dB) was made possible by
replacing a ﬁxed resistance of the ultrasound electronic
board with a variable, manually adjusted resistance in
order to achieve a gain from 6 dB to )80 dB. The signal
amplitude level was controlled using the standard
maintenance software provided with ultrasound device.
This electronic modiﬁcation of the system enables the
simulation of a loss of sensitivity of the receiving stage
(i.e. the receiving probe, A1, A2 and the ﬁlter): 5, 10, 15,
20, 25, 30, 35, 40, 45, 50, 56 dB.
Variation of transfer function at emission
The simulation of the transfer function variation at the
emission stage was possible by addition of a variable
resistance from 0 to 10 kW (Fig. 5). When the resistance
is ﬁxed at 10 kW, normal working conditions of the
UBIS-5000 are obtained. The further the value of this
resistance is decreased, the more the emitting voltage
decreases, thus resulting in a reduction of the amplitude
of the emitting ultrasound signal. Due to the sensitivity
of the variable resistance, it was not possible to start
with a mild amplitude variation. The signal amplitude
loss ranged from )25 to )56 dB compared with the
baseline, which was ﬁxed at 0 dB.
Modiﬁcation of footbath temperature
A switch on the UBIS hardware allowed a technician to
modify the water temperature control from 27 to 33C in
steps of 2C. We were able to increase the tested tem-
perature range by adding hot or cold water (with sur-
factant). The obtained temperature range varied from 25
to 36.5C.
Malfunctioning transducer
The pair of normally working transducers on the
UBIS-5000 was successively replaced by two pairs of
malfunctioning transducers, with a gain loss of about
8.5 dB and )36 dB, respectively. Apart from the
probe, all the electronics remained unchanged. The
results were compared with baseline data on variation
of the transfer function at the reception stage. The
real malfunction (malfunctioning transducers) was
evaluated against the simulated malfunction (a varia-
tion of transfer function at the reception stage) in
order to verify the validity of the malfunctioning
probe model.
Statistical methods
The normality assumption of the dataset was evaluated
using the JMP statistical package (version 3.2.2; SAS
Institute Inc.). In vivo and in vitro data were then
summarized using descriptive statistics (mean, standard
deviation, minimum and maximum). These calculations
were performed for baseline measurements and for each
level of all simulated malfunctions. The eﬀect of each
simulated malfunction on in vivo and in vitro results was
presented graphically by plotting the average BUA val-
ues against the percentage change from baseline. The
change from baseline in BUA was modeled using linear
regression, and the in vivo/in vitro ratio was obtained
from the model.
Table 1 General statistics for baseline measurements
In vitro In vivo (n=12) Temperature
BUAP1 (dB/MHz) BUAP2 (dB/MHz) BUA (dB/MHz) Age (years) Weight (kg) Height(cm) T (C)
Mean value 39.13 81.50 61.56 41.0 57.75 166.17 31.5
SD 0.11 0.66 4.24 14.3 8.62 11.54 0.47
Min 38.83 79.71 53.00 28.2 47.00 151.00 30.4
Max 39.35 82.93 72.20 71.5 80.00 189.00 32.6
Fig. 4 Block diagram of system electronics: reception stage
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Results
Baseline measurements were collected for each volun-
teer, leading to a total of 76 baseline measurements for
both digital phantoms, BUAP1 and BUAP2. The impact
of the simulations of the ultrasound measurements is
reported below.
Variation of transfer function at reception
At every modiﬁcation of gain, each subject was mea-
sured twice and the mean BUA value was calculated.
For each subject, the diﬀerence from baseline was then
calculated and expressed in percentage. The results of
the experiments are summarized in Table 2 and Fig. 6.
The 95% conﬁdence interval (CI) of the in vitro (1.7%)
and in vivo precision (1.9%) is represented in Fig. 6. All
variations of data outside of given limits are considered
to be signiﬁcant. BUAP2 reached a peak around 15 dB
of amplitude loss, while BUAP1 reached its peak around
35 dB. The BUA (expressed in percentage) values then
decreased, undershot and returned to the baseline level
for BUAP1, while they remained lower than the baseline
for BUAP2. A similar pattern was observed in vivo,
where the BUA value increased with the decrease in gain
and reached a peak at around 45 dB. The BUA value
then decreased below the baseline level. When consid-
ering the in vitro and in vivo precision at 95% CI, the in
vitro values reached a signiﬁcant level quite rapidly (at
5 dB of gain loss), whereas none of the in vivo values
reached the signiﬁcance level before 35 dB of gain loss.
Variation of the transfer function at emission
We simulated malfunction of the emission electronics by
altering the voltage of the signal driving the ultrasound
emitter using a variable resistance. Due to the sensitivity
of the potentiometer, we were not able to measure a loss
in emission inferior to 25 dB with suﬃcient precision.
The simulated malfunction, when applied in vivo,
showed that a decrease in the voltage resulted in an
increase in the BUA values (Table 3 and Fig. 7).
It appears that the digital normal phantom was less
sensitive to a mild loss of signal amplitude than the
osteoporotic one. The osteoporotic phantom increases
Table 2 Variation of transfer function at reception
Subtracted gain, dB na Mean BUAdB/MHz Mean SD Diﬀerence to the base-
line, %
P1 P2 In vivo P1 P2 In vivo P1 P2 In vivo
0 76 39.13 81.50 61.68 0.11 0.66 0.37 0.00 0.00 0
5 24 40.18 82.75 61.53 0.08 0.58 0.34 2.68 1.53 )0.25
10 24 40.63 86.18 61.87 0.05 0.71 0.30 3.85 5.75 0.31
15 24 41.28 89.10 61.95 0.12 0.57 0.31 5.50 9.33 0.44
20 23 42.59 87.12 62.13 0.17 0.50 0.18 8.84 6.90 0.73
25 24 43.44 84.33 62.17 0.10 0.42 0.33 11.02 3.48 0.78
30 24 45.67 80.55 62.38 0.31 0.52 0.21 16.72 )1.17 1.13
35 24 47.37 76.95 62.86 0.22 0.60 0.31 21.07 )5.59 1.89
40 24 43.89 76.85 63.25 0.40 0.85 0.48 12.16 )5.70 2.47
45 24 37.91 76.82 63.50 0.49 1.02 0.27 )3.11 )5.74 2.89
50 24 39.20 74.07 62.03 0.23 2.09 0.31 0.19 )9.11 0.52
56 21 39.23 74.49 59.82 0.33 2.42 0.36 0.27 )8.60 )3.06
aTotal number of measurements per experimentation
Fig. 5 Block diagram of the system electronics: emission stage
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its value to reach a peak around 30 dB and then de-
creases. In contrast, the normal phantom was stable
until about 25 dB and then decreased with a pattern
similar to the osteoporotic phantom. The beginning of
the curve for the in vivo BUA is relatively ﬂat, followed
by a slight increase. This increase started at around 25–
30 dB loss at the emitting stage. It is important to note
that above 30–35 dB of loss, the UBIS software will
trigger an alarm due to electronic fault. As a conse-
quence, the eﬀect of such a malfunction will be minimal
in the authorized range of functioning.
In vivo/in vitro ratio
In order to analyse the loss of signal amplitude mal-
function we used ultrasound values up to the amplitude
peak of the osteoporotic digital phantom ()35 dB), be-
cause they follow a predictable pattern. The data beyond
this point are aﬀected by the limitations of the internal
electronics of the UBIS-5000 and become useless for the
analysis. Furthermore, an alarm will be triggered when a
distortion of more than 30–35 dB is recorded by the
system. As a consequence, we detected trends before the
device reached a level of malfunction corresponding to
this peak. Allowing trends to be detected after this point
would imply that the measured values become unre-
coverable.
The measurements on digital phantoms were found
to be as sensitive to the simulated malfunction as the
in vivo measurements. According to the correlation
coeﬃcient, 92% of the variation in vivo is explained
by the in vitro simulation (Fig. 8). The in vitro/in vivo
ratio was estimated to be about 1/10 for the BUA
variation in amplitude at the reception stage, for both
phantoms, and about 1/16 for the emission up to the
peak of the BUAP1 phantom, corresponding about
)35 dB. Nevertheless, it is diﬃcult to have conﬁdence
in the regression slope (linking the in vitro and in vivo
data in the simulation at emission) and to make a
sensible conclusion based on insuﬃcient number of
time points.
Fig. 6 Result of the gain loss at
the reception stage on the in
vivo and in vitro (digital
phantoms) BUA
measurements. Results are
expressed as a percentage of
baselines. The 95% conﬁdence
interval of the in vitro and in
vivo precision is represented by
dotted area
Table 3 Variation of transfer function at emission
Subtracted gain, dB na Mean BUAdB/MHz Mean SD Diﬀerence to the baseline, %
P1 P2 In vivo P1 P2 In vivo P1 P2 In vivo
0 76 39.13 81.50 61.45 0.11 0.66 0.37 0 0 0
25 22 59.44 77.16 61.97 10.98 22.49 0.51 51.9 )5.3 0.5
30 24 60.78 67.00 62.26 10.79 23.89 0.44 55.3 )17.8 1.3
35 24 57.28 59.04 62.72 8.03 19.49 0.28 46.4 )27.6 2.1
40 24 50.90 48.29 62.16 4.81 18.45 0.24 30.1 )40.7 1.3
45 24 43.73 28.98 60.40 6.09 13.42 0.37 11.7 )64.4 )1.4
50 24 40.71 19.75 56.40 8.22 9.00 0.57 4.0 )75.8 )7.8
56 24 34.12 15.94 50.88 6.36 11.04 0.99 )12.8 )80.4 )16.7
aTotal number of measurements per experimentation
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Modiﬁcation of footbath temperature
According to the regression slope (regression not
shown), a temperature variation of 1C corresponds to
an increase in the BUAP1 value by 0.012 dB/MHz, that
is 0.03% (and 0.045 dB/MHz 0.05% for BUAP2).
Since the device is temperature controlled at 30C±2C
(out of this range, an alarm will be triggered), the total
BUAP1 variation for the temperature change of 4C
will be equal to 0.046 dB/MHz or 0.11% (and 0.18 dB/
MHz or 0.20% for the BUAP2). That value is 3–6
times less than the in vitro precision for the digital
phantom.
Malfunctioning transducer
We veriﬁed the validity of the malfunction’s simulation
in the case of a loss of signal amplitude at the reception
stage, in vivo as well as in vitro, by creating a real
breakdown using transducers with a known loss of
sensitivity. The two broken transducers showed a loss of
sensitivity of )10 dB and 36 dB, respectively. The results
of the real breakdown were expressed as a percentage
with respect to baseline, and were then compared with
theoretical simulated values (Table 4). The simulated
malfunction and the real breakdown produce the same
tendency and a similar magnitude in BUA changes.
Fig. 8 The ratio BUAP1 value
versus in vivo average value
calculated from the experience
of gain at the reception stage.
The ratio enables us to estimate
the sensitivity of the digital
phantom in detecting
malfunction compared to real
subject data and to apply the
appropriate correction factor to
in vivo data based on the in
vitro results
Fig. 7 Result of the gain loss at
the emission stage on the in vivo
and in vitro (digital phantoms)
BUA measurements. Results
are expressed as a percentage of
baselines. The 95% conﬁdence
interval of the in vitro and in
vivo precision is represented by
the dotted area
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Discussion
The internal digital phantom allows automatic calibra-
tion of the device. The advantage of the digital phantom
is its ease of use, since it does not require any manipu-
lations during the measurement, thus avoiding posi-
tioning errors. In addition, the inﬂuence of external
factors on digital phantoms, such as aging and temper-
ature, should be less pronounced than on external
phantoms. As a consequence, internal phantoms are
expected to have a much smaller drift than external
phantoms in short- and long-term use.
We studied the impact of malfunction simulations on
BUA values by simultaneously measuring the calca-
neous of 12 volunteers and the digital phantom. The in
vivo group was ﬁrst divided into two subgroups aiming
to represent osteoporotic and normal populations
(subjects with low values and normal values), but since
no diﬀerences were found either in the ultrasound signal
pattern or in the results, we decided to pool all subjects’
values in the same group. Overall, our data are very
comparable with results from a previous exploratory
study [17,18], suggesting the reproducibility of our
experiment.
The impact of the transfer function variation in the
receiving signal exists on the in-vivo ultrasound
parameters, and is overall directly proportional to the
malfunction. However, this impact barely reaches a
signiﬁcant level compared with the in-vivo precision of
the QUS, and after a substantial deterioration of the
signal (at least )25 dB). Moreover, we can clearly see a
deterioration of the image quality around 40 dB of
amplitude loss or greater. In addition to the alarm set at
)35 dB, the visual quality control of the examination
should enable the capture of such images and classify
them as poor quality. It is very interesting to observe
that in vivo and in vitro results show an identical curve
shape when simulating the malfunction of loss of signal
amplitude. We observed a parallel increase in BUA and
gain until the maximum peak and a steep decrease after
that point. The attenuation compares the signal ampli-
tude that passes through the reference material (water)
to the signal amplitude that passes through the sample
(bone), and is expressed in dB. The BUA is the slope of
the linear regression over the attenuation curve as a
function of frequency. The same principle is applied to
digital phantoms, but the bone behavior is simulated by
the device itself. During the simulated malfunction, we
reduced the transfer function by modifying the ﬁxed
gain of the ampliﬁer A1 (Fig. 4), thus changing the
attenuation. In the example of the BUA curve of the
osteoporotic phantom (Fig. 6), several regions corre-
sponding to diﬀerent parts of this simulation, can be
observed: (1) the ﬁrst part of the curve (up to point A)
shows the behavior of the device with an unmodiﬁed or
slightly modiﬁed gain; (2) the section between points A
and B in the curve illustrates how the UBIS-5000 reads a
progressively increasing BUA as the gain of the ampliﬁer
is reduced (impacting the transfer function); (3) when the
gain in ampliﬁer A1 is reduced, we also reduce the
amplitude of the signals (in water and through bone) at
the output. At point B, the signal becomes extremely
weak and at high frequencies this signal is even weaker
than the background noise. The more the gain of A1 is
reduced, the larger will be the portion of the signal curve
that is covered by the background noise. Since the noise
amplitude is larger than the signal amplitude in this area,
the measurements will give the false impression that the
signal is less attenuated than it really is. Consequently,
the calculated attenuation curve will become progres-
sively ﬂatter, resulting in a decreased BUA, which ap-
pears between B and C; and (4) at point C, the gain of
A1 is so reduced that A2 is set to its maximum gain by
the software. A further decrease in the gain of A1 cannot
be compensated by an increased gain in A2, resulting in
a decreased signal after the ampliﬁcation chain
(A1+A2). The signal measured at this point is probably
perceived as a weaker signal through bone, leading to
the interpretation that the bone shows a higher attenu-
ation. Consequently, the measured BUA increases with
a decreased gain in A1 (behavior after point C).
The impact of loss of amplitude of the emitting signal is
not as clear as the previous experiment (reception stage).
Nevertheless, there is an inﬂuence of the emitting signal on
the in vivo ultrasound parameters, which also does not
reach signiﬁcance compared to the in vivo precision.
Based on our experiment, it appears that the tem-
perature ﬂuctuation of the water bath in the working
range of the UBIS-5000 does not inﬂuence ultrasound
measurements in vitro. This result is not surprising, since
at the level of frequencies used to generate these ultra-
sounds, the attenuations in water are very small. In
comparison with the most commonly used external
phantoms, Njeh has demonstrated that an increase in
temperature of 1C caused an increase of 0.1-0.4% in
BUA in the Leeds phantom, and an increase of 0.1-1.6%
in the Vancouver phantom [19]. Krieg has observed with
the Achilles black rubber phantom that for each increase
of 1C, BUA decreased by )0.6 dB/MHz, and SOS by
)4.3 m/s (P<0.001 for all three correlations). In our
study, a temperature variation of 1C causes the BUA to
increase by 0.03% with the osteoporotic phantom and
by 0.05% with the normal phantom.
The in vitro/in vivo ratio of 1–10.35 (or even more
for the speed of sound 60.54) plays a favorable role
Table 4 In vivo versus in vitro comparison: malfunctioning trans-
ducer in percentage of baseline value. Values are given as per-
centages
BUA P1 BUA P2 In vivo BUA
Gain loss of 36 dB
Simulated malfunction 16.5 )4.0 2.9
Real breakdown 17.5 )9.5 3.1
Gain loss of )10 dB
Simulated malfunction 3.8 4.5 0.3
Real breakdown 4.0 3.0 0.3
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in the QC approach and highlights the higher sensi-
tivity of the phantom in detecting breakdowns. The
digital phantoms identify even small variations of gain
prior to the in vivo observation. That means that any
shift or drift of the apparatus, at least during loss of
signal amplitude on the reception (or emission at a
lesser extent) stage malfunction, will be registered by
digital phantoms before the failure of the machine
inﬂuences the in vivo results. Indeed, when considering
an in vivo precision of 0.66% for BUA, to have
conﬁdence in the impact of the malfunction in vivo at
95% CI (i.e. about 1.9% for the BUA), one must
observe about 20% (10.35·1.9) deviation from
baseline in vitro for BUA. The early detection of de-
vice malfunction will allow the system to be repaired
immediately, or for a retrospective correction of the in
vivo data to be made by applying the correction fac-
tor. Therefore, the patient results will be due to bio-
logical or therapeutic eﬀect and not due to incorrect
device performance. This is the ﬁrst time that the ratio
between in vivo and in vitro in QC application has
been investigated.
The favorable results of the digital phantoms have
two possible explanations: (1) the good linearity of the
electronics in the working range, and (2) the digital
phantoms are working at a lower voltage (63 V, 20 V
and 2 V) than in vivo measurements (200 V). Small
variations at the emission or reception will be more
easily captured if the emission voltage is low (2 V). This
explains why the osteoporotic digital phantom is more
sensitive to malfunction.
Overall, when considering the loss of amplitude in
emission or reception of up to 35 dB (beyond that point
an alarm is triggered), none of the experiments signiﬁ-
cantly inﬂuenced the in vivo results (when considering
the 95% CI of the in vivo precision). As a result, the
stability of the device is well captured by the digital
phantom with minimal in vivo impact within the mon-
itored range. Out of the two BUA parameters generated
by the digital phantom, BUAP1 corresponds better to
the usual studied populations in clinical trials and is
more sensitive to emission and reception malfunctions.
Nevertheless, the BUAP2, the pattern of which diﬀers
between the two experiments, could be used to diﬀer-
entiate the type of malfunction and the subsequent type
of correction.
There are some limitations to our study. Indeed, this
work is relevant only when applied to the use of the
UBIS-5000 devices, since some aspects of the study
depend on limitations derived from the device’s elec-
tronics design. These limitations, depending on engi-
neering choices, can be diﬀerent from one type of
device to another. Hence, some reasoning valid for the
UBIS-5000 might be erroneous when applied to a de-
vice from a diﬀerent manufacturer. Although SOS is
measured by the UBIS devices, it is not reported by the
manufacturer on the patient printout. Furthermore, the
digital phantom does not measure the SOS parameter.
As such, it was decided not to study the SOS in this
experimentation. Nevertheless, the water SOS could be
also be used to monitor the stability of the device if
needed, as was suggested by Hans et al., who co-
developed the methodology for the Achilles device [11].
A similar approach should be applied for each indi-
vidual ultrasound device of diﬀerent brands, because
their own characteristics may diﬀer from UBIS-5000. In
addition, we studied only the most common malfunc-
tions and did not cover the whole spectrum of all
possible malfunctions. Even though there are limita-
tions in our approach, the results indicate that the
sensitivity of the digital phantoms is reliable in the
monitoring of device instability and malfunctions. As a
result, one could imagine that all water based devices
could use this digital phantom. For dry systems, the
digital phantom developed by Langton et al. [13] could
be an alternative, although it would need to be veriﬁed
and tested.
In conclusion, the sensitivity of digital phantoms is
reliable in the determination of simulated malfunctions
of the UBIS-5000. The digital phantoms provide an
accurate evaluation of the acoustic performance of the
scanner, including the ﬁdelity of transducers. In light of
these results, the QC approach of the UBIS-5000 will be
extremely simple to implement compared with other
devices. Indeed, since the digital phantom is automati-
cally measured during each patient measurement, the
QC approach could be built on an individual level basis
rather than on an average basis.
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